Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling by Fujita, Takashi et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
©
 
 The Rockefeller University Press, 0021-9525/2004/07/85/11 $8.00
The Journal of Cell Biology, Volume 166, Number 1, July 5, 2004 85–95
http://www.jcb.org/cgi/doi/10.1083/jcb.200401138
 
JCB
 
Article
 
85
 
Runx2 induces osteoblast and chondrocyte 
differentiation and enhances their migration 
by coupling with PI3K-Akt signaling
 
Takashi Fujita,
 
1
 
 Yasutaka Azuma,
 
2
 
 Ryo Fukuyama,
 
3,4
 
 Yuji Hattori,
 
1
 
 Carolina Yoshida,
 
4,5
 
 Masao Koida,
 
1
 
 
Kiyokazu Ogita,
 
1
 
 and Toshihisa Komori
 
4
 
1
 
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata 573-0101, Japan
 
2
 
Department of Pharmacology, Osaka Dental University, Hirakata 573-1121, Japan
 
3
 
Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure 737-0112, Japan
 
4
 
Division of Oral Cytology and Cell Biology, Department of Developmental and Reconstructive Medicine, Nagasaki University 
Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan
 
5
 
Department of Orthodontics and Dentofacial Orthopedics, Osaka University Faculty of Dentistry, Suita, Osaka 565-0871, Japan
 
unx2 and phosphatidylinositol 3-kinase (PI3K)–Akt
signaling play important roles in osteoblast and chon-
drocyte differentiation. We investigated the relationship
between Runx2 and PI3K-Akt signaling. Forced expression
of 
 
Runx2
 
 enhanced osteoblastic differentiation of C3H10T1/2
and MC3T3-E1 cells and enhanced chondrogenic differen-
tiation of ATDC5 cells, whereas these effects were blocked
by treatment with IGF-I antibody or LY294002 or adeno-
viral introduction of dominant-negative (dn)–
 
Akt
 
. Forced
expression of 
 
Runx2
 
 or dn-
 
Runx2
 
 enhanced or inhibited
cell migration, respectively, whereas the enhancement by
R
 
Runx2 was abolished by treatment with LY294002 or
adenoviral introduction of dn-
 
Akt
 
. Runx2 up-regulated
PI3K subunits (p85 and p110
 
 
 
) and Akt, and their expression
patterns were similar to that of Runx2 in growth plates.
Treatment with LY294002 or introduction of dn-
 
Akt
 
 severely
diminished DNA binding of Runx2 and Runx2-dependent
transcription, whereas forced expression of myr
 
Akt
 
 en-
hanced them. These ﬁndings demonstrate that Runx2 and
PI3K-Akt signaling are mutually dependent on each other
in the regulation of osteoblast and chondrocyte differentiation
and their migration.
 
Introduction
 
The formation of bone structures in vertebrates involves
osteoblast and chondrocyte differentiation. Osteoblast and
chondrocyte differentiation are regulated by many secreted
differentiation factors including TGF
 
 
 
s, bone morphoge-
netic proteins, insulin-like growth factors (IGFs), FGFs,
parathyroid hormone (PTH), PTH–related peptide, thyroid
hormone, Indian hedgehog, and retinoic acid (Karaplis,
2002). Furthermore, transcription factors play fundamental
roles in osteoblast and chondrocyte differentiation. Runx2
(runt-related transcription factor 2)/Cbfa1 (core binding
factor 
 
 
 
1)/Pebp2
 
 
 
A (polyoma enhancer binding protein
2
 
 
 
A) and Osterix are essential for osteoblast differentiation
(Komori et al., 1997, Otto et al., 1997, Nakashima et al.,
2002); Sox5, Sox6, and Sox9 are essential for chondrocyte
differentiation (Bi et al., 1999, Smits et al., 2001); and
Runx2 plays an important role in terminal chondrocyte dif-
ferentiation (Enomoto et al., 2000, Ueta et al., 2001).
Runx2 is a transcription factor that belongs to the Runx
family (Komori 2002). 
 
Runx2
 
-deficient (
 
Runx2
 
 
 
/
 
 
 
) mice
completely lack bone formation owing to the absence of
osteoblasts (Komori et al., 1997, Otto et al., 1997). Runx2
determines the osteoblast lineage from multipotent mesen-
chymal cells, induces osteoblastic differentiation at the early
stage, and inhibits it at the late stage (Liu et al., 2001, Komori
2002). Further, Runx2 has been shown to induce alkaline
phosphatase (ALP) activity, expression of bone matrix pro-
tein genes, and mineralization in immature mesenchymal
cells and osteoblastic cells in vitro (Banerjee et al., 1997,
Ducy et al., 1997, Harada et al., 1999). Chondrocyte differ-
entiation is also disturbed in 
 
Runx2
 
 
 
/
 
 
 
 mice (Inada et al.,
1999, Kim et al., 1999). Overexpression of 
 
Runx2
 
 or the
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dominant-negative (dn) form of 
 
Runx2
 
 (dn-
 
Runx2
 
) in chon-
drocytes accelerates or decelerates chondrocyte matura-
tion, respectively, indicating that Runx2 is a positive reg-
ulatory factor in chondrocyte maturation (Ueta et al.,
2001). Further, introduction of dn-
 
Runx2
 
 inhibited cell
condensation in insulin-induced chondrogenesis of
ATDC5 cells (Akiyama et al., 1999). Thus, Runx2 plays
crucial roles in osteoblast and chondrocyte differentiation
(Komori 2002).
Mutant mice that lack both 
 
Igf1
 
 and 
 
Igf2
 
 and mice that
lack the 
 
Igf1r
 
 show severe retardation of bone development,
and both 
 
Irs1
 
-deficient mice and 
 
Irs2
 
-deficient mice show
an osteopenic phenotype (Liu et al., 1993, Ogata et al.,
2000, Akune et al., 2002). Therefore, IGFs and their signal-
ing molecules play important roles in skeletal development
by regulating osteoblast and chondrocyte differentiation.
Akt is a serine-threonine kinase whose amino terminus con-
tains a pleckstrin homology, and is activated by various ex-
tracellular stimuli including insulin and IGF through the
phosphatidylinositol 3-kinase (PI3K) pathway (Scheid and
Woodgett, 2001). In various cell culture systems, PI3K-Akt
signaling has been implicated as a critical pathway for the
differentiation of skeletal component cells including chon-
drocytes, osteoblasts, myoblasts, and adipocytes (Kaliman et
al., 1996, Sakaue et al., 1998, Hidaka et al., 2001, Ghosh-
Choudhury et al., 2002). Further, bone development is se-
verely delayed in mice lacking both 
 
Akt1
 
 and 
 
Akt2
 
 (Peng et
al., 2003). However, the mechanism of the differentiation of
skeletal component cells mediated by PI3K-Akt signaling re-
mains to be clarified.
PDGF, IGF, and VEGF work as chemotactic factors
through PI3K, and PI3K-Akt signaling is a major pathway
for chemotaxis through G-protein–coupled receptors in 
 
Dic-
tyostelium discoideum 
 
and in neutrophils and through tyro-
sine kinase receptors in fibroblasts. After activation of PI3K
at the leading edge, Akt rapidly accumulates by binding to
PtdIns(3,4,5)P
 
3
 
 via its pleckstrin homology domain, leading
to activation of Akt by phosphorylation. Akt likely mediates
cell migration at least partly by activating Rac and p21-acti-
vated protein kinase (Ridley et al., 2003).
Although Runx2 is an important transcription factor for
osteoblast and chondrocyte differentiation, and PI3K-Akt
signaling is deeply involved in the differentiation of skeletal
component cells, the relationship between Runx2 and PI3K-
Akt signaling is not known. In this study, we investigated
the involvement of PI3K-Akt signaling in the function of
Runx2 using immature mesenchymal C3H10T1/2 cells, im-
mature osteoblastic MC3T3-E1 cells, and prechondrogenic
ATDC5 cells, and found that Runx2 induces osteoblast and
chondrocyte differentiation and enhances their migration by
coupling with PI3K-Akt signaling.
 
Results
 
PI3K-Akt signaling is involved in Runx2-dependent 
osteoblast differentiation
 
To elucidate if PI3K-Akt signaling is involved in Runx2-
dependent osteoblast and chondrocyte differentiation, we
established 
 
Runx2
 
 or dn-
 
Runx2
 
 stable transfectants from an
immature osteoblastic cell line, MC3T3-E1, an immature
mesenchymal cell line, C3H10T1/2, and an insulin-depen-
dent prechondrogenic cell line, ATDC5 (Fig. 1, A and B).
The differentiation of MC3T3-E1 cells was enhanced in
 
Runx2
 
 stable transfectants but inhibited in dn-
 
Runx2
 
 stable
transfectants in comparison with that in the wild-type
MC3T3-E1 cells, as indicated by the levels of ALP activity
and calcium deposition (Fig. 2, A and B). MC3T3-E1 cells
secrete IGF-I (Huang et al., 2000). The Runx2-induced en-
hancement of ALP activity and mineralization was blocked
by treatment with either a neutralizing antibody against
IGF-I or a PI3K inhibitor, LY294002, in a dose-dependent
manner (Fig. 2 C), indicating that IGF-I receptor-PI3K sig-
naling is required for Runx2 activity in MC3T3-E1 cells.
Further, adenoviral introduction of dn-
 
Akt
 
 blocked Runx2-
induced ALP activity and mineralization (Fig. 2 D). ALP ac-
tivity was also induced in 
 
Runx2
 
 stable transfectants from
C3H10T1/2 cells, whereas it was abrogated by adenoviral
introduction of dn-
 
Akt
 
 (Fig. 2 E). These findings indicate
that PI3K-Akt signaling is involved in Runx2-dependent os-
teoblast differentiation.
Figure 1. Establishment of Runx2 or dn-Runx2 stable transfectants. 
Runx2 or dn-Runx2 stable transfectants were established from 
C3H10T1/2, MC3T3-E1, and ATDC5 cells as described in Materials 
and methods. The expression level of Runx2 was examined by Western 
blot analysis (A) and that of dn-Runx2 was examined by Western 
blot (A) and Northern blot (B) analyses. (A) The arrows show the 
bands for endogenous and exogenous Runx2 protein expression 
or exogenous dn-Runx2 protein expression. (B) Arrows show the 
bands for exogenous dn-Runx2 mRNA. Arrowheads show the bands 
for endogenous Runx2 mRNA. White lines indicate that intervening 
lanes have been spliced out. wt, wild-type cells. Representative data 
from four to five independent clones are shown. Dn-Runx2 protein 
was detected using an anti-Runx2 antibody, which specifically 
recognizes the NH2 terminus of Runx2. 
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PI3K-Akt signaling is involved in Runx2-dependent 
chondrocyte differentiation
 
We investigated whether or not PI3K-Akt signaling is in-
volved in Runx2-dependent chondrocyte differentiation us-
ing ATDC5 cells. ATDC5 cells express 
 
Col1a1
 
 until the
cells reach confluence. After confluence, ATDC5 cells con-
densate and show chondrogenic characteristics including
proteoglycan synthesis and 
 
Col2a1
 
 expression in the pres-
ence of insulin (Shukunami et al., 1996). Further, ATDC5
cells mature to hypertrophic chondrocytes, which express
 
Col10a1
 
 (Enomoto et al., 2000). Adenoviral introduction of
 
Runx2
 
 promoted proteoglycan synthesis and 
 
Col2a1
 
 expres-
sion and then 
 
Col10a1
 
 expression, whereas treatment with
LY294002 completely prevented proteoglycan production
and 
 
Col2a1
 
 and 
 
Col10a1
 
 expression in 
 
Runx2
 
-overexpress-
ing cells (Fig. 3). Further, adenoviral introduction of dn-
 
Akt
 
attenuated the Runx2-enhanced proteoglycan production
and 
 
Col2a1
 
 and 
 
Col10a1
 
 expression (Fig. 3). These findings
indicate that PI3K-Akt signaling is involved in Runx2-induced
chondrocyte differentiation of ATDC5 cells.
 
Runx2 controls cell migration through PI3K-Akt signaling
 
When PI3K-Akt signaling was inhibited, Runx2-depen-
dent osteoblast and chondrocyte differentiation were abol-
Figure 2. Blockage of PI3K-Akt signal-
ing inhibits Runx2-dependent osteoblast 
differentiation . After confluence, wild-
type cells and Runx2 or dn-Runx2 stable 
transfectants of MC3T3-E1 cells (A–D) 
and C3H10T1/2 cells (E) were cultured 
with 50  g/ml ascorbic acid and 10 mM 
 -glycerophosphate and were examined 
for ALP activity after culture for 3 d and 
for mineralization after culture for 7 d. 
ALP activity (A) and the calcium content 
(B) in wild-type MC3T3-E1 cells (wt) and 
Runx2 or dn-Runx2 stably transfected 
MC3T3-E1 cells. ALP activities in two 
independent clones (#1 and #2) are 
presented as mean   SEM of six wells. 
*, P   0.05; **, P   0.001 versus wild-
type cells. Calcium contents are shown 
as mean   SEM of six wells. (C) Runx2 
transfectants were treated with anti–IGF-I 
antibody or LY294002 at the indicated 
concentrations, and ALP activity (top 
wells) and mineralization (bottom wells) 
were examined. ALP activities and 
calcium contents in two independent 
clones (#1 and #2) are presented as 
mean   SEM of four wells. *, P   0.05; 
**, P   0.001 versus cells without anti–
IGF-I antibody and LY294002 treatment. 
(D) Runx2 stable transfectants were 
infected with EGFP- or dn-Akt-expressing 
adenovirus, and ALP activity (top wells) 
and mineralization (bottom wells) were 
examined. ALP activities and calcium 
contents in two independent Runx2 stable 
clones (Rinx2#1 and Runx2#2) are pre-
sented as mean   SEM of four wells. *, 
P   0.001 versus EGFP-expressing adeno-
virus-infected cells. (E) Wild-type cells 
(wt) and Runx2 stable transfectants (Runx2) 
of C3H10T1/2 cells were infected with 
EGFP- or dn-Akt–expressing adenovirus, 
and ALP activity was examined. ALP 
activities in wild-type and two indepen-
dent Runx2 stable clones (Rinx2#1 and 
Runx2#2) are presented as mean   SEM 
of four wells. *, P   0.001 versus EGFP-
expressing adenovirus-infected wild-
type cells. #, P   0.001 versus EGFP-
expressing adenovirus infected Runx2 
stable clone. In each experiment, similar 
results were obtained using at least three 
independent stable clones. 
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ished. Therefore, we examined cell migration, which is
controlled by PI3K-Akt signaling, in chemotaxis assays us-
ing 
 
Runx2
 
 or dn-
 
Runx2
 
 stable transfectants from MC3T3-
E1 cells. Random migration was enhanced in the 
 
Runx2
 
stable transfectants both in the absence or presence of a
chemotactic factor, PDGF, compared with that in wild-
type MC3T3-E1 cells, whereas it was suppressed in the
dn-
 
Runx2
 
 stable transfectants, indicating that Runx2 en-
hances cell motility (Fig. 4, A and B). Further, PDGF-
induced chemotaxis was enhanced in the 
 
Runx2
 
 stable trans-
fectants compared with that in the wild-type cells, whereas
it was suppressed in the dn-
 
Runx2
 
 stable transfectants.
Similar results were obtained using 
 
Runx2
 
 or dn-
 
Runx2
 
stable transfectants from C3T10T1/2 cells and ATDC5
Figure 3. Blockage of PI3K-Akt signaling 
inhibits Runx2-dependent chondrogenic 
differentiation of ATDC5 cells. (A) Alcian 
blue staining. (B) Northern blot analysis 
of Col2a1 and Col10a1 mRNA expression. 
ATDC5 cells were infected with EGFP-
expressing adenovirus (EGFP), both EGFP- 
and Runx2-and-EGFP (Runx2)–expressing 
adenoviruses, or both Runx2-and-EGFP– 
and dn-Akt (dn-Akt)–expressing adeno-
viruses. After infection, the cells were 
cultured for 8 d with or without 20  M 
LY294002 and stained with Alcian blue 
(A). In other cells, after infection, RNA 
was extracted on the indicated days of 
culture with or without 20  M LY294002, 
and Col2a1 and Col10a1 expression 
were examined by Northern blot analysis 
(B). GAPDH was used as an internal 
control. Similar results were obtained in 
three independent experiments and rep-
resentative data are shown.
Figure 4. Runx2 controls cell migration. Wild-type 
MC3T3-E1 cells and Runx2 or dn-Runx2 stably trans-
fected MC3T3-E1 cells were cultured in the Boyden 
chamber in the absence or presence of the indicated 
concentrations of PDGF, and chemotaxis was evalu-
ated as described in Materials and methods. Photo-
graph of the assay filter (A) and the number of cells that 
migrated to the lower side of the filter (B, Migrated cell 
number). PDGF was added in the lower wells of the 
Boyden chamber, except in the random migration 
experiments in which 100 ng/ml PDGF was added in 
both the upper and lower wells. Data are presented as 
mean   SEM of four wells. *, P   0.05; **, P   0.005 
versus wild-type cells at the respective concentration. 
(C) 100 ng/ml PDGF was added in the lower wells of 
the Boyden chamber, and wild-type (wt) and Runx2 
stably transfected (Runx2) MC3T3-E1 cells were cultured 
in the absence or presence of 10  M LY294002. Data 
are presented as mean   SEM of four wells. *, P   0.05 
versus wild-type cells. #, P   0.005 versus Runx2 stable 
transfectants without LY294002 treatment. (D) Wild-type 
MC3T3-E1 cells were cultured in  -MEM containing 
0.1% FCS for 48 h, and then the cells were cultured in 
the absence or presence of 10  M LY294002 for 30 
min before the addition of PDGF. 50  g of lysates from 
cells that had or had not been treated with 100 ng/ml 
PDGF for 30 min was examined by Western blot 
analysis using anti-phospho-Akt antibody. (E) Wild-type 
MC3T3-E1 cells (wt) and Runx2 stably transfected 
MC3T3-E1 cells (Runx2) were infected with EGFP- or 
dn-Akt–expressing adenovirus. Data are presented as 
mean   SEM of four wells. *, P   0.01 versus the 
respective wild-type cells. #, P   0.005 versus the 
respective Runx2 stable transfectants infected with EGFP-
expressing adenovirus. In B, C, and E, four separate 
experiments using independent stable clones were 
performed and representative data are shown.Coupling of Runx2 and PI3K-Akt signaling | Fujita et al. 89
cells (unpublished data). Treatment with LY294002 com-
pletely abolished the PDGF-induced chemotaxis of Runx2
stable transfectants (Fig. 4 C). Indeed, PDGF induced phos-
phorylation of Akt in wild-type MC3T3-E1, C3T10T1/2,
and ATDC5 cells, which were inhibited by treatment with
LY294002 (Fig. 4 D and not depicted). Adenoviral intro-
duction of dn-Akt into Runx2 stable transfectants abol-
ished the enhancement of chemotaxis induced by Runx2
in the cell migration assay (Fig. 4 E). Similar results were
also obtained using MC3T3-E1 cells infected with Runx2-
expressing adenovirus (unpublished data). These findings
indicate that Runx2 enhances cell migration through PI3K-
Akt signaling.
Runx2 up-regulates PI3K and Akt protein levels
To investigate whether or not Runx2 affects PI3K-Akt sig-
naling, we examined the expression levels of the PI3K sub-
units, p85 and p110, and Akt in Runx2 or dn-Runx2 stably
transfected cells by Western blot analysis (Fig. 5). Overex-
pression of Runx2 up-regulated the levels of p85, p110 ,
and Akt in C3H10T1/2, MC3T3-E1, and ATDC5 cells.
Further, phosphorylated Akt was increased in parallel with
the level of total Akt protein. In contrast, overexpression of
dn-Runx2 down-regulated the levels of p85, p110 , and Akt
proteins in MC3T3-E1 cells and ATDC5 cells. There were
no differences in the levels of p110  and p110  proteins
among the wild-type cells, Runx2 stable transfectants and
dn-Runx2 stable transfectants in the C3H10T1/2 cells,
MC3T3-E1 cells, and ATDC5 cells. p110  was up-regu-
lated only in the Runx2 stably transfected MC3T3-E1 cells
compared with the respective wild-type cells. These findings
indicate that Runx2 positively regulates PI3K-Akt signaling
by up-regulating the p85, p110 , and Akt protein levels in
immature mesenchymal cells, immature osteoblastic cells,
and prechondrogenic cells.
We next examined if up-regulation of p85, p110 , and
Akt protein levels was due to the transcriptional regulation
by RT-PCR analysis. Overexpression of Runx2 up-regulated
mRNA for p110  in C3H10T1/2, MC3T3-E1, and ATDC5
cells, whereas overexpression of dn-Runx2 down-regulated
mRNA for p110  in MC3T3-E1 and ATDC5 cells. mRNAs
for p85 , Akt1, Akt2, and Akt3 were also mildly up-regu-
lated by overexpression of Runx2, but mRNAs for p85 ,
Akt1, Akt2 were subtly down-regulated by overexpression of
dn-Runx2. In p85 , there was no transcriptional regulation
by Runx2. Therefore, these findings indicate that p110  is
mainly regulated by Runx2 at transcriptional level, whereas
p85 and Akt are regulated by Runx2 at both transcriptional
and protein levels.
As the levels of p85, p110 , and Akt proteins were up-
regulated by Runx2, their expression patterns in tibial
growth plates were examined in wild-type mouse embryos
at E16.5 by immunohistochemistry. The p85, p110 , and
Akt protein levels were up-regulated at the stage of prehy-
pertrophic chondrocytes, which express Pthr1, and the up-
regulation was maintained in hypertrophic chondrocytes,
which express Col10a1 (Fig. 6). The Runx2 protein level
was also up-regulated at the stage of prehypertrophic chon-
drocytes (Fig. 6; Inada et al., 1999; Kim et al., 1999;
Enomoto et al., 2000). Therefore, we also examined p85,
p110 , and Akt expression in the tibial growth plates of
dn-Runx2 transgenic embryos under the control of the
Col2a1 promoter (Ueta et al., 2001) at E18.5. Up-regula-
tion of p85, p110 , and Akt protein levels was not ob-
Figure 5. Western blot and RT-PCR analyses of PI3K subunits 
(p85 and p110) and Akt. (A) The expression of p85, p110 , p110 , 
p110 , p110 , phosphorylated Akt (phospho-Akt), and Akt proteins 
was compared among wild-type (wt) and Runx2 or dn-Runx2 stably 
transfected cells of C3H10T1/2, MC3T3-E1, or ATDC5 cells by 
Western blot analysis. 20  g of lysates was loaded. The ratios of 
phosphorylated Akt versus total Akt are shown in the bottom. The 
ratio of phosphorylated Akt versus total Akt in wild-type cells of 
each cell line was defined as one, and relative values are shown. 
Data are presented as mean   SEM of three independent experiments. 
In each cell line, similar results were obtained using three independent 
stable clones. Arrows show the bands for the indicated proteins. 
White lines indicate that intervening lanes have been spliced out. 
(B) The expression of p85 , p85 , p110 , Akt1, Akt2, and Akt3 
mRNA was compared among wild-type (wt) and Runx2 or dn-Runx2 
stably transfected cells of C3H10T1/2, MC3T3-E1, or ATDC5 cells 
by RT-PCR analysis. HPRT was used as an internal control. In 
each cell line, similar results were obtained using three independent 
stable clones.90 The Journal of Cell Biology | Volume 166, Number 1, 2004
served in dn-Runx2 transgenic embryos, suggesting that
Runx2 is involved in the regulation of p85, p110 , and
Akt expression in growth plates.
PI3K-Akt signaling enhances DNA binding of Runx2 
and Runx2-dependent transcription
We found that treatment of Runx2 stable transfectants
from C3H10T1/2 cells with U0126, a MEK inhibitor, or
LY294002 inhibited ALP activity in a dose-dependent man-
ner (Fig. 7 A). To investigate how PI3K-Akt signaling is in-
volved in the activity of Runx2, we examined the effects of
LY294002 on the DNA binding of Runx2 and Runx2-
dependent transcription, and compared them with the effects
of U0126. On electrophoretic mobility shift assay (EMSA)
using OSE2 oligonucleotides that contain a Runx binding
site, nuclear extracts from Runx2 stable transfectants of
C3H10T1/2 cells formed specific Runx2-Cbfb-DNA com-
plexes (Fig. 7 B). However, treatment of the Runx2 stable
transfectants with LY294002 for 30 min drastically reduced
the DNA-binding capacity of Runx2 to less than one-tenth
(Fig. 7, B and C). In contrast, treatment of the cells with
U0126 for 30 min had no effect on the DNA-binding ca-
pacity of Runx2 (Fig. 7 B), although prolonged treatment
for 24 h gradually reduced the DNA binding of Runx2 up
to one-fourth (Fig. 7 C). Treatment with LY294002 or
U0126 did not affect the level of Runx2 protein in the
Runx2 stable transfectants (Fig. 7 B). In reporter assays using
the osteocalcin promoter, treatment with either LY294002
or U0126 for 48 h severely reduced the level of Runx2-
dependent transcription in Runx2 stable transfectants from
C3H10T1/2 cells (Fig. 7 D). Further, chromatin immuno-
precipitation assays showed that treatment with LY294002
prevented the binding of Runx2 to endogenous osteocalcin
promoter in wild-type MC3T3-E1 cells (Fig. 7 E). These
findings indicate that the DNA-binding capacity of Runx2
and transcriptional activation by Runx2 are dependent on
the activities of both PI3K and MEK, but the mechanisms
through which PI3K and MEK regulate Runx2 function are
quite different.
As the treatment with anti–IGF-I antibody severely inhib-
ited osteoblastic differentiation of MC3T3-E1 cells (Fig. 2 C),
we further examined the effect of the treatment with
anti–IGF-I antibody in the DNA binding of Runx2. The
DNA binding of Runx2 was diminished by the treatment
with anti–IGF-I antibody (Fig. 7 F). However, overexpres-
sion of Runx2 failed to induce Igf1 (Fig. 7 G). These find-
ings indicate that Runx2 is not involved in Igf1 induction,
but IGF-I signaling plays an important role in Runx2-
dependent osteoblastic differentiation of MC3T3-E1 cells.
Next, we examined the DNA binding of Runx2 and
Runx2-dependent transcription in myrAkt and dn-Akt sta-
ble transfectants. DNA binding of Runx2 was strongly en-
hanced in myrAkt stable transfectants of MC3T3-E1 cells
compared with that in wild-type MC3T3-E1 cells (Fig.
8 A). In reporter assays using the osteocalcin promoter,
Runx2-dependent transcription was strongly enhanced in
the myrAkt stable transfectants, but was absent in dn-Akt
stable transfectants of MC3T3-E1 cells (Fig. 8 B). However,
overexpression of myrAkt or dn-Akt did not affect the pro-
tein levels of Runx2 or Cbfb (Fig. 8 C). Adenoviral in-
troduction of dn-Akt in Runx2 stable transfectants of
C3H10T1/2 cells severely reduced the DNA binding of
Runx2 (Fig. 8 D). In reporter assays using the osteocalcin
promoter, introduction of dn-Akt in Runx2 stable trans-
Figure 6. Runx2, PI3K subunits, and Akt expression in tibial growth 
plates. The expression patterns of Runx2 (A and B), p85 (C and D), 
p110  (E and F), and Akt (G and H) in tibial growth plates from 
wild-type mice at E16.5 (A, C, E, and G) and dn-Runx2 transgenic 
(dn-Runx2 tg) mice under the control of Col2a1 promoter at E18.5 
(B, D, F, and H) were examined by immunohistochemistry using 
anti-Runx2, anti-p85, anti-p110 , and anti-Akt antibodies. To clarify 
the differentiation stage of chondrocytes, the expression of Pthr1 
(I and J) and Col10a1 (K and L) in tibial growth plates from wild-type 
mice at E16.5 (I and K) and dn-Runx2 transgenic mice at E18.5 
(J and L) was examined by in situ hybridization using antisense probes 
of Pthr1 and Col10a1. We detected no signal using the sense probes 
of Pthr1 and Col10a1 (not depicted). Bars, 100  m.Coupling of Runx2 and PI3K-Akt signaling | Fujita et al. 91
fectants of C3H10T1/2 cells dose dependently inhibited
Runx2-dependent transcription, which was similar to the ef-
fect of dn-Runx2 (Fig. 8 E). These findings indicate that
PI3K-Akt signaling plays an important role in the DNA
binding of Runx2 and transcriptional activation by Runx2.
We further examined whether or not Akt is involved in
the phosphorylation of Runx2 by immunoprecipitation
assays using anti-Runx2 antibody in myrAkt-transfected
ATDC5 cells. The phosphorylation levels of tyrosine, serine,
and threonine in Runx2 were similar between wild-type and
myrAkt-transfected ATDC5 cells (Fig. 8 F). Further, a simi-
lar level of Runx2 was detected in wild-type and myrAkt-
transfected ATDC5 cells in the immunoprecipitation assays
using antiphosphotyrosine, antiphosphoserine, or antiphos-
phothreonine antibody (unpublished data). These findings
suggest that phosphorylation of Runx2 is not a major mech-
anism for the activation of Runx2 by Akt.
Discussion
We showed that PI3K-Akt signaling is deeply involved in
Runx2-dependent osteoblast and chondrocyte differentia-
tion and their migration. Runx2 enhanced PI3K-Akt signal-
ing by up-regulating the protein levels of PI3K subunits and
Figure 7. Inhibitors of PI3K and MEK inhibit DNA binding of Runx2 and Runx2-dependent transcription. (A) After confluence, Runx2 
transfectants were treated with U0126 or LY294002 at the indicated concentrations for 3 d and ALP activity was examined. Three separate 
experiments using independent stable clones were performed and representative data are shown. (B) On EMSA using OSE2 oligonucleotides, 
nuclear extract from Runx2 stably transfected C3T10T1/2 cells showed a specific band (arrows), which was competitively bound by unlabeled 
OSE2 oligonucleotides (lane 2, 100-fold molar excess), but not by mutated oligonucleotides (lane 3, 100-fold molar excess). Addition of antibody 
against Runx2 supershifted the specific band (lane 4), and addition of antibody against Cbfb prevented formation of the specific Runx2-Cbfb-DNA 
complexes (lane 5). Treatment with 10  M LY294002 for 30 min, but not with 20  M U0126 for 30 min, prevented the formation of the specific 
Runx2-Cbfb-DNA complexes (lanes 7 and 8). Asterisk indicates the supershifted complexes, and arrowheads indicate nonspecific bands. 
The level of Runx2 protein was examined in the nuclear extracts of lanes 6–8 by Western blot analysis (bottom panel). White line indicates 
that an intervening lane has been spliced out. (C) DNA-binding activity of Runx2 was examined at the indicated times after the addition of 10  M 
LY294002 or 20  M U0126 to the cell cultures. The intensity of Runx2-DNA complexes in Runx2 stably transfected C3H10T1/2 cells before 
LY294002 or U0126 treatment was defined as 100, and the relative intensities are shown. The data are presented as mean   SEM of four 
independent experiments. Three separate experiments were performed, and they showed similar results. (D) Reporter assays using the osteocalcin 
promoter. Runx2 stably transfected C3H10T1/2 cells were transiently transfected with p147mOG2/luciferase reporter construct (p147-luc). 
After culture for 24 h, the medium was replaced with medium containing 2% FCS and the transfected cells were cultured without or with 10 
 M LY294002 or 20  M U0126 for 48 h. Data are presented as mean   SEM of four wells. *, P   0.005 versus cells without LY294002 and 
U0126 treatment. Four separate experiments using independent stable clones were performed, and representative data are shown. (E) Chromatin 
immunoprecipitation assay. After the culture for 3 d in medium containing ascorbic acid, MC3T3-E1 cells were cultured with or without 10  M 
LY294002 for 30 min, and samples were prepared as described in Materials and methods. After chromatin immunoprecipitation by anti-Runx2 
antibody, purified DNAs from immunoprecipitates without Ly294002 treatment (lane1), immunoprecipitates with LY294002 treatment (lane 
2), supernatants without LY294002 treatment (lane 3), and supernatants with LY294002 treatment (lane 4) were amplified by PCR using the 
primers in the mouse osteocalcin promoter region. Chromatin immunoprecipitation was also performed using anti-HA antibody as a negative 
control, and no specific band was amplified using purified DNA from immunoprecipitates without Ly294002 treatment (lane 5). (F) Runx2 
stable transfectants of MC3T3-E1 cells were treated with 80  g/ml IGF-I antibody for 3 d, and EMSA was performed using OES2 oligonucleotides. 
(G) RT-PCR analysis of Igf1 expression. After confluence, wild-type and Runx2 stably transfected MC-3T3-E1 cells were cultured for 3 d in the 
presence of ascorbic acid, and mRNAs were isolated for RT-PCR. HPRT was used as an internal control.92 The Journal of Cell Biology | Volume 166, Number 1, 2004
Akt, whereas PI3K-Akt signaling greatly enhanced DNA
binding of Runx2 and Runx2-dependent transcription. This
positive feedback loop further augments Runx2 activity in
osteoblast and chondrocyte differentiation and their migra-
tion. Thus, our findings indicate that Runx2 and PI3K-Akt
signaling are mutually dependent on each other in the reg-
ulation of osteoblast and chondrocyte differentiation and
their migration.
Treatment with LY294002 or introduction of dn-Akt
severely inhibited Runx2-induced osteoblastic and chon-
drogenic differentiation of C3H10T1/2, MC3T3-E1, and
ATDC5 cells (Figs. 2 and 3), indicating that PI3K-Akt sig-
naling is involved in Runx2 functioning at multiple steps of
osteoblast differentiation as well as chondrocyte differentia-
tion. MAPK-dependent phosphorylation of Runx2 stimu-
lates Runx2-dependent transcription (Xiao et al., 2000), and
protein kinase A phosphorylates the transactivation domain
of Runx2 (Selvamurugan et al., 2000). In contrast, Runx2 is
negatively regulated by serine phosphorylation (Wee et al.,
2002). Treatment with LY294002 for 30 min severely di-
minished DNA binding of Runx2 without affecting the lev-
els of both Runx2 and Cbfb proteins (Fig. 7), but the phos-
phorylation levels of tyrosine, serine, and threonine in
Runx2 were not affected by the overexpression of myrAkt
(Fig. 8 F). Although a possibility that Akt modulates phos-
phorylation of Runx2 cannot be excluded, it is possible that
PI3K-Akt signaling regulates the DNA-binding activity of
Runx2 by phosphorylation of some molecules that form a
DNA-binding complex with Runx2 or their dephosphoryla-
tion through the activation of phosphatase, because interac-
tions with other transcription factors such as Ets, Smads,
and C/EBP, with the transcription cofactor Rb, and with
the transcriptional repressor TLE greatly influence the activ-
ity of Runx2 (Komori, 2002). However, the mechanism of
the phosphorylation or dephosphorylation of DNA-binding
complex molecules containing Runx2 by PI3K-Akt signal-
ing should be different from that by the MAPK pathway be-
cause the time courses of the inhibition of the DNA-binding
activity of Runx2 were quite different between the treat-
ments with LY294002 and U0126 (Fig. 7 C).
In accordance with our findings, bone development in Igf1/
Igf2 mutant mice, Igf1r mutant mice, and Akt1/Akt2 mutant
mice is severely delayed (Liu et al., 1993, Peng et al., 2003).
However, the delay in bone development in these mutant
mice is still milder than that in Runx2
 /  mice (Komori et al.,
1997, Otto et al., 1997), suggesting that stimulation with
other ligands such as VEGF in addition to IGFs may also be
involved in the activation of PI3K-Akt signaling, and that
Akt3 in addition to Akt1 and Akt2 may function in osteoblast
and chondrocyte differentiation. However, in the case of
MC3T3-E1 cells it is likely that IGF-I is a major ligand for
the activation of PI3K-Akt signaling and Runx2 function and
Figure 8. Akt regulates DNA binding 
of Runx2 and Runx2-dependent tran-
scription. (A) EMSA using cell lysates 
from wild-type and myrAkt stably trans-
fected MC3T3-E1 cells. The intensity of 
the specific band (arrow) was greatly 
enhanced in myrAkt stably transfected 
MC3T3-E1 cells. The specific band was 
competitively bound by unlabeled OSE2 
oligonucleotides (wt, 100-fold molar 
excess), but not by mutated OSE2 oligo-
nucleotides (mut, 100-fold molar excess). 
The addition of Runx2 antibody super-
shifted the specific band (asterisk). 
Arrowhead indicates nonspecific bands. 
(B) Reporter assays using the osteocalcin 
promoter. Wild-type MC3T3-E1 cells 
and myrAkt or dn-Akt stably transfected 
MC3T3-E1 cells were transiently trans-
fected with p147-luc. Data are presented 
as mean   SEM of four wells. *, P   0.05 
versus wild-type cells. (C) Western blot 
analysis. Nuclear extracts and whole-
cell lysates were prepared from wild-
type MC3T3-E1 cells and myrAkt or 
dn-Akt stably transfected MC3T3-E1 
cells. 10  g of nuclear extracts was loaded 
and the filter was hybridized with anti-
Runx2 antibody. 20  g of whole-cell lysates was loaded and the filters were hybridized with anti-Cbfb antibody or anti-Akt antibody. 
(D) Wild-type cells (wt) and Runx2 stable transfectants (Runx2) of C3H10T1/2 cells were infected with EGFP- or dn-Akt-expressing adenovirus. 
EMSA was performed using OSE2 oligonucleotides. The introduction of dn-Akt inhibited the formation of Runx2-DNA complexes (arrow). 
Arrowhead indicates nonspecific bands. (E) The indicated amounts of dn-Runx2 or dn-Akt construct were transiently cotransfected with 
p147-luc in Runx2 stably transfected C3H10T1/2 cells. Data are presented as mean   SEM of four wells. *, P   0.05; **, P   0.005 versus 
cells without transfection of dn-Runx2 and dn-Akt. In each experimental condition, four separate experiments using independent stable 
clones were performed and representative data are shown. (F) The level of phosphorylation of Runx2. Nuclear extracts from wild-type and 
myrAkt stable transfected ATDC5 cells at confluence were immunoprecipitated using anti-Runx2 antibody, and the immunoprecipitates were 
transferred to nylon membranes and reacted with antiphosphotyrosine, antiphosphoserine, or antiphosphothreonine antibody. Four independent 
experiments showed similar results, and representative data are shown.Coupling of Runx2 and PI3K-Akt signaling | Fujita et al. 93
that autocrine stimulation by IGF-I is important for differen-
tiation because treatment with anti–IGF-I antibody severely
inhibited the osteoblastic differentiation induced by Runx2
and DNA binding of Runx2 (Fig. 2 C and Fig. 7 F).
In growth plates, proliferating chondrocytes begin to ma-
ture to prehypertrophic chondrocytes and further mature to
hypertrophic chondrocytes. In this maturation process, the
Runx2, p85, p110 , and Akt protein levels were all up-regu-
lated at the stage of prehypertrophic chondrocytes, and the
up-regulation was maintained during the hypertrophic stage
(Fig. 6). Further, Runx2 up-regulated the p85, p110 , and
Akt protein levels (Fig. 5), and PI3K-Akt signaling activated
Runx2 function (Figs. 7 and 8). Therefore, the positive feed-
back loop of Runx2 and PI3K-Akt signaling is likely to play
important roles in the maturational process of chondrocytes
at the growth plates.
We showed that Runx2 is involved in cell migration.
Runx2 increased chemotaxis of C3H10T1/2, MC3T3-E1,
and ATDC5 cells, and it was abrogated by treatment with
LY294002 or the introduction of dn-Akt (Fig. 4 and not
depicted), indicating that Runx2 induces cell migration
through PI3K-Akt signaling. However, as IGF-I has no sig-
nificant effect on the cell migration of MC3T3-E1 cells
(Fukuyama et al., 2004), activation of another signaling
pathway in addition to PI3K-Akt signaling pathway may be
required for the cell migration, and Runx2 may be involved
in the activation of both signaling pathways. The signifi-
cance of chemotaxis in bone and cartilage formation has not
been shown. However, as Runx2 is expressed in the precur-
sors of osteoblasts and chondrocytes (Ducy et al., 1997,
Otto et al., 1997), Runx2 may play a role in the migration
of these precursors to the appropriate sites during skeletal
development. Runx2 may also play a role in bone remodel-
ing by inducing the migration of osteoblasts to the surface of
bone that has undergone osteolysis by osteoclasts. As Runx2
expression is strongly induced in osteoblastic cells after bone
fracture (Kawahata et al., 2003), chemotaxis enhanced by
Runx2 should be important for the migration of osteoblastic
cells to the healing area. Indeed, after a bone fracture, the
positive feedback loop of Runx2 and PI3K-Akt signaling
would play important roles in multiple healing processes in-
cluding the migration of chondrogenic and osteoblastic cells
and their precursors to the healing place, chondrocyte matu-
ration that leads to the replacement of cartilage with bone,
and osteoblast differentiation.
We showed the linkage of Runx2 and the PI3K-Akt sig-
naling pathway in osteoblast and chondrocyte differentia-
tion and their migration. However, PI3K-Akt signaling is
involved in multiple cell functions including cell prolifera-
tion, apoptosis, cell growth, and glucose metabolism in ad-
dition to cell differentiation and migration. Therefore, the
cell phenotypes resulting from the coupling of Runx2 and
PI3K-Akt signaling may be more complex, and they need to
be further investigated.
Materials and methods
Cell cultures
C3H10T1/2 and ATDC5 cells were purchased from RIKEN Cell Bank.
MC3T3-E1 subclone 4 was a gift from R.T. Franceschi (University of Mich-
igan School of Dentistry, Ann Arbor, MI; Xiao et al., 2000). C3H10T1/2
cells were cultured in BME and MC3T3-E1 cells were cultured in  -MEM
containing 10% FBS (GIBCO BRL). ATDC5 cells were cultured as previ-
ously described (Enomoto et al., 2000). Cells were treated with anti–IGF-I
antibody (Upstate Biotechnology), LY294002 (Calbiochem), or U0126
(Calbiochem). The percentages of dead cells, which were less than 3% by
a trypan blue exclusion assay, were not significantly different among all of
the experiments.
Establishment of stably transfected cells
To generate a dn-Runx2-expressing vector, a 421-bp DNA fragment con-
taining the runt domain of Runx2 was subcloned into pSG5 (Stratagene).
The vectors, myrAkt, which has the c-Src myristoylation sequence fused in
frame to the NH2 terminus of the Akt coding sequence, and dn-Akt [T308A,
S473A], were gifts from K. Walsh (St. Elizabeth’s Medical Center, Boston,
MA; Fujio et al., 1999). The day before transfection, cells were plated on
35-mm dishes at a density of 10
5 cells per milliliter. Runx2-expressing vec-
tor (Harada et al., 1999), dn-Runx2-expressing vector, myrAkt-expressing
vector, or dn-Akt-expressing vector was transfected using FuGENE 6 (Roche).
A vector containing the neomycin-resistant gene and the respective vector
were cotransfected in the cells. Cells were grown to subconfluence,
trypsinized, plated at low density, and selected in the presence of 400  g/
ml G418 for 3 wk. Colonies were isolated by digestion with trypsin/EDTA
for 5 min at 37 C within stainless steel cloning rings. Four to five indepen-
dent clones were established in each expression vector.
Adenoviral transfer
Bicistronic adenovirus vectors expressing type II Runx2 and EGFP or EGFP
alone were generated as previously described (Yoshida et al., 2002). Dn-
Akt–expressing adenovirus was a gift from K. Walsh (Fujio et al., 1999).
Cells were plated at a density of 2   10
4 cells per well in 24-well plates.
They were infected with EGFP-expressing, Runx2-and-EGFP–expressing,
and/or dn-Akt–expressing adenoviruses at a multiplicity of infection of 10
or 20 for 12 or 24 h.
Cytochemical and immunohistochemical examinations and
in situ hybridization
Detection and quantification of ALP activity, von Kossa staining, Alizarin
red staining, and calcium quantification were performed as described pre-
viously (Enomoto et al., 2000; Kobayashi et al., 2000). Dn-Runx2 trans-
genic mice were generated as previously described (Ueta et al., 2001). Im-
munohistochemical analysis was performed using rabbit anti-p85 (Upstate
Biotechnology), rabbit anti-p110  (Santa Cruz Biotechnology, Inc.), rabbit
anti-Akt (New England Biolabs, Inc.), or mouse monoclonal anti-Runx2
(Yoshida et al., 2002) antibody as described previously (Liu et al., 2001). In
situ hybridization was performed using a 0.8-kb fragment of mouse Pthr1
cDNA and a 0.65-kb fragment of mouse Col10a1 cDNA for probes as pre-
viously described (Ueta et al., 2001). Sections were counterstained with
methyl green. The images were acquired by Axioskop 2 Plus (Carl Zeiss
MicroImaging, Inc.) with an objective lens (PlanNeofluar, 40 /0.75) and
AxioCam HRc (Carl Zeiss MicroImaging, Inc.) using AxioVision 3.0 at
22 C. The images were processed in size and brightness using Adobe Pho-
toshop 5.5. Before the study, all experiments were reviewed and approved
by Osaka University Medical School Animal Care and Use Committee.
Northern blot and RT-PCR
Northern blot was performed using a 0.4-kb fragment of mouse Col2a1
cDNA, a 0.65-kb fragment of mouse Col10a1 cDNA, and a 0.85-kb frag-
ment of mouse GAPDH cDNA, as described previously (Inada et al.,
1999). For RT-PCR, cDNA (10 ng total RNA equivalent) was amplified by
Amp Taq DNA polymerase (PerkinElmer) using the following primers:
p85 , 5 -ATTTCACCCCCTACTCCCAA-3  and 5 -GGCTGTCTCTCATTC-
CATTC-3 ; p85 , 5 -CGCAACACGGACAGACTGGT-3  and 5 -TAGCAG-
CAGCACAGGGAAGT-3 ;  p110 , 5 -CTGTGACCCCGCAGAAAAAT-3 
and 5 -CATACTCCACTCTCCCACTG-3 ; Akt1, 5 -CGTAGCCATTGTGAA-
GGAGG-3  and 5 -CCCTTGCCCAGTAGTTTCAG-3 ;  Akt2, 5 -GTCG-
CCAACAGTCTGAAGCA-3  and 5 -GAGAGAGGTGGAAAAACAGC-3 ;
Akt3, 5 -AAGGTTGGGTTCAGAAGAGG-3  and 5 -CTGTGAGGTTGG-
GCTACAAT-3 ; hypoxanthin guanine phosphoribosyl transferase (HPRT),
5 -GCTGGTGAAAAGGACCTCT-3  and 5 -CACAGGACTAGAACAAC-
TGC-3 ; Igf1, 5 -GCTCTGCTTGCTCACCTTCA-3  and 5 -CGATAGGGA-
CGGGGACTTCT-3 . 25 cycles (p85 ), 20 cycles (p85 ,  p110 ,  Akt1,
Akt2, Akt3, and Igf1), and 15 cycles (HPRT) of amplification were per-
formed using a Gene Amp PCR system 2400 (PerkinElmer; 30 s at 94 C, 30 s
at 64 C, and 1 min at 72 C). Amplified products were verified by subclon-
ing and sequence analysis. PCR products were transferred to nylon mem-
branes and hybridized with the respective 
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Western blot and immunoprecipitation analyses
Western blot analyses were performed using nuclear extracts or whole cell
lysates as described previously (Yoshida et al., 2002). The blots were first in-
cubated with rabbit anti-p85 antibody, which recognizes both p85  and
p85  (Upstate Biotechnology); rabbit anti-p110  antibody; rabbit anti-
p110  antibody; rabbit anti-p110  antibody; rabbit anti-p110  antibody
(Santa Cruz Biotechnology, Inc.); rabbit anti-Akt antibody, which recog-
nizes Akt1, Akt2, and Akt3 (New England Biolabs, Inc.); rabbit anti-phos-
pho-Akt antibody (New England Biolabs, Inc.); goat anti-Runx2 antibody
(Santa Cruz Biotechnology, Inc.); or monoclonal Cbfb antibody (a gift from
Y. Ito, Institute of Molecular and Cell Biology, Singapore; Yoshida et al.,
2002); and then with HRP-conjugated anti–rabbit or anti–mouse IgG (New
England Biolabs, Inc.) or anti–goat IgG (Santa Cruz Biotechnology, Inc.). Im-
munoprecipitation was performed using Seize™X protein G immunopre-
cipitation kit (Pierce Chemical Co.) to avoid contamination of IgG band ac-
cording to the manufacturer’s protocol using nuclear extract samples, anti-
Runx2 antibody (Santa Cruz Biotechnology, Inc.), and antiphosphotyrosine,
antiphosphoserine, and antiphosphothreonine mAbs (Seikagaku Corp.).
Cell migration assay
Cell migration assays were performed using PDGF-BB (PeproTech) as de-
scribed previously (Fukuyama et al., 2004). Cells were placed in the upper
wells at 10
5 cells per well. After culture for 12 h, the filters were removed,
fixed in 100% methanol, and stained with Diff-Quick (International Re-
agent Corp.). The top side of the filter was then scraped free of cells with a
cotton swab. The number of cells that migrated to the bottom side was
counted manually.
EMSA
Nuclear extracts were prepared, and EMSA was performed as described
previously (Yoshida et al., 2002). Competition was performed with either a
100-fold molar excess of unlabeled OSE2 oligonucleotides or a 100-fold
molar excess of mutated oligonucleotides. For supershift experiments,
mAb against Runx2 or Cbfb (gifts from Y. Ito; Yoshida et al., 2002) was
added to the entire mixture. Protein–DNA complexes were resolved on
6% nondenaturing polyacrylamide gels.
Reporter assay
Reporter assays were performed by transient transfection of 0.2  g of
p147mOG2/Luciferase reporter construct (p147-luc) and 0.002  g of pRL-
CMV using Dual Luciferase Reporter Assay System (Promega) as described
previously (Yoshida et al., 2002). Luciferase activity was measured using a
model TD20/20 luminometer (Promega) and normalized to Renilla lu-
ciferase activity under the control of CMV promoter.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation was performed as described previously
(Yoshida et al., 2004). After immunoprecipitation using anti-Runx2 anti-
body (Santa Cruz Biotechnology, Inc.), DNAs were purified from the su-
pernatants and immunoprecipitates, respectively. PCR was performed us-
ing the following primers in the promoter region ( 471/ 67) of the mouse
osteocalcin gene: CTGAACTGGGCAAATGAGGACA and AGGGGATGC-
TGCCAGGACTAAT.
Statistical analysis
Statistical analyses were performed using t test. P   0.05 was considered
to be significant.
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